Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, June Weon Cheong, Barbara Pro et al.|The Lancet|2018

Cited by 733